Use of anti-amyloid therapies for Alzheimer's disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.
Breno José Alencar Pires Barbosa, Elisa de Paula França Resende, Raphael Machado Castilhos, Wyllians Vendramini Borelli, Norberto Anízio Ferreira Frota, Marcio Luiz Figueredo Balthazar, Augusto Celso Scarparo Amato, Jerusa Smid, Maira Tonidandel Barbosa, Artur Martins Coutinho, Leonardo Cruz de Souza, Lucas Porcello Schilling, Mari Nilva Maia da Silva, Gustavo Bruniera Peres Fernandes, Paulo Henrique Ferreira Bertolucci, Ricardo Nitrini, Eliasz Engelhardt, Orestes Vicente Forlenza, Paulo Caramelli, Sonia Maria Dozzi Brucki, Adalberto Studart
{"title":"Use of anti-amyloid therapies for Alzheimer's disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.","authors":"Breno José Alencar Pires Barbosa, Elisa de Paula França Resende, Raphael Machado Castilhos, Wyllians Vendramini Borelli, Norberto Anízio Ferreira Frota, Marcio Luiz Figueredo Balthazar, Augusto Celso Scarparo Amato, Jerusa Smid, Maira Tonidandel Barbosa, Artur Martins Coutinho, Leonardo Cruz de Souza, Lucas Porcello Schilling, Mari Nilva Maia da Silva, Gustavo Bruniera Peres Fernandes, Paulo Henrique Ferreira Bertolucci, Ricardo Nitrini, Eliasz Engelhardt, Orestes Vicente Forlenza, Paulo Caramelli, Sonia Maria Dozzi Brucki, Adalberto Studart","doi":"10.1590/1980-5764-DN-2024-C002","DOIUrl":null,"url":null,"abstract":"<p><p>Novel therapies for Alzheimer's disease, particularly anti-amyloid drugs like lecanemab and donanemab, have shown modest clinical benefits but also significant risks. The present paper highlights the challenges of access to diagnosis, cost-effectiveness, safety, and the need for more representation of diverse populations in clinical trials. Recommendations include careful patient selection, risk-benefit analysis, and the importance of proven amyloid pathology for treatment. Future work involves further research on anti-amyloid therapies in Brazil and the development of more effective treatments for Alzheimer's disease.</p>","PeriodicalId":39167,"journal":{"name":"Dementia e Neuropsychologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556288/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia e Neuropsychologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/1980-5764-DN-2024-C002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Novel therapies for Alzheimer's disease, particularly anti-amyloid drugs like lecanemab and donanemab, have shown modest clinical benefits but also significant risks. The present paper highlights the challenges of access to diagnosis, cost-effectiveness, safety, and the need for more representation of diverse populations in clinical trials. Recommendations include careful patient selection, risk-benefit analysis, and the importance of proven amyloid pathology for treatment. Future work involves further research on anti-amyloid therapies in Brazil and the development of more effective treatments for Alzheimer's disease.
期刊介绍：
Dementia top Neuropsychologia the official scientific journal of the Cognitive Neurology and Ageing Department of the Brazilian Academy of Neurology and of the Brazilian Association of Geriatric Neuropsychiatry, is published by the "Associação Neurologia Cognitiva e do Comportamento", a nonprofit Brazilian association. Regularly published on March, June, September, and December since 2007.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
